Revvity (Revvity) Price-to-Operating-Cash-Flow

: 134.90 (As of Today)

View and export this data going back to 1983. Start your Free Trial

As of today (2024-04-23), Revvity's share price is $100.77. Revvity's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.75. Hence, Revvity's Price-to-Operating-Cash-Flow Ratio for today is 134.90.

The historical rank and industry rank for Revvity's Price-to-Operating-Cash-Flow or its related term are showing as below:

RVTY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.16 Med: 23.31 Max: 426.99
Current: 134.95

During the past 13 years, Revvity's highest Price-to-Operating-Cash-Flow Ratio was 426.99. The lowest was 11.16. And the median was 23.31.

RVTY's Price-to-Operating-Cash-Flow is ranked worse than
96.55% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 18.03 vs RVTY: 134.95

Revvity's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $1.59. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.75.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Revvity was -86.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -54.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -12.80% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 6.20% per year.

During the past 13 years, Revvity's highest 3-Year average Operating Cash Flow per Share Growth Rate was 63.10% per year. The lowest was -54.90% per year. And the median was 3.20% per year.

Revvity Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Revvity's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

29.79

18.03

16.63

26.08

149.53

Revvity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																26.08	36.61	66.36	432.42	149.53

Competitive Comparison

For the Diagnostics & Research subindustry, Revvity's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revvity Price-to-Operating-Cash-Flow Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Revvity's Price-to-Operating-Cash-Flow falls into.

Revvity Price-to-Operating-Cash-Flow Calculation

Revvity's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	100.77	/	0.747
	=	134.90

Revvity's Share Price of today is $100.77.
Revvity's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.75.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Revvity Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Revvity's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Revvity (Revvity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

PKN:Germany PKN:Germany

Address

940 Winter Street, Waltham, MA, USA, 02451

Website

https://www.revvity.com

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Executives

Anita Gonzales	officer: Please See Remarks	940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra	officer: Please See Remarks	940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg	officer: See Remarks	940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor	officer: Please See Remarks	940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett	director	C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas	director	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121